Furthermore, a therapeutic blockade of CD47 by antibodies or suppression of CD47 expression is sufficient to enhance the direct TCR-dependent killing of tumor cells by mouse or human CD8 T cells [9,10]. This evidence concerns the gene CD8A and neoplasm.